RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells) As I've already stated It should be easy to enroll 180-200 patients because (1) patients who have progressed from Enhertu will already have been identified as those who are eligible for 3rd line pelareorep + paclitaxel treatment making it a seamless transition from the ADC treatment to pelareorep, and (2) patients will be recruited from the United States and the EU, where patients populations are high and where patient types are diverse and demonstrated to have responded to pelareorep in several clinical trials already performed. So a number of 180-200 should be easy to reach by ONCY or whatever Big Pharma company that acquires ONCY and runs the trial themselves.